It was hypothesized that because AOSD and SJIA are closely related conditions, genes that respond to canakinumab treatment in patients with SJIA may be inversely dysregulated in patients with AOSD prior to anti − IL-1β therapy. This evidence concerns the gene IL1B and adult-onset Still disease.